17:09 , May 3, 2019 |  BC Week In Review  |  Clinical News

GT Biopharma leveraging NK cells to treat HIV

GT Biopharma is expanding its immuno-oncology platform into HIV thanks to work by its partner suggesting the company's TriKE modality could move the needle from life-long therapies to cures. GT Biopharma Inc. (Pink:GTBP) said April...
23:31 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal muscular atrophy (SMA) Cell culture and mouse studies suggest inhibiting SQSTM1 could help treat SMA, which is caused by SMN1 mutations. In motor neuron cells derived from a mouse model of SMA or...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Financial News

Oxis proposes private placement of units

Oxis International Inc. (OTCQB:OXIS; Euronext:OXI), Beverly Hills, Calif.   Business: Nutraceuticals, Cancer   Date announced: 2016-08-24   Type: Private placement of units   To be raised: Up to $10 million   Units: 50 million  ...
02:14 , Jan 26, 2016 |  BC Extra  |  Clinical News

Relypsa gains on DDI data

Relypsa Inc. (NASDAQ:RLYP) gained $3.28 to $22.90 in early after-hours trading Monday after reporting data from Phase I drug-drug interaction studies of hyperkalemia drug Veltassa patiromer . Veltassa was approved in October 2015 with a...
07:00 , Oct 26, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/23 cls Biogen Inc. (NASDAQ:BIIB) Baird Brian Skorney Price target Neutral 2% $276.99 H.C. Wainwright Andrew Fein Price target Buy...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

University of Minnesota, Oxis deal

Two researchers at the university granted Oxis exclusive, worldwide rights to develop and commercialize DT2219ARL . The researchers will receive an upfront payment and are eligible for milestones, plus royalties. The product is a bispecific...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

University of Minnesota, Oxis deal

Two researchers at the university granted Oxis exclusive, worldwide rights to develop and commercialize DT2219ARL . The researchers will receive an upfront payment and are eligible for milestones, plus royalties. The product is a bispecific...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Company News

University of Pittsburgh, Oxis deal

The partners amended a January deal granting Oxis’ Oxis Biotech Inc. subsidiary exclusive, worldwide rights to develop and commercialize P62 chemical agents to treat multiple myeloma (MM) to include patent rights related to the addition...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Company News

MultiCell Technologies Inc, Oxis deal

Oxis and MultiCell’s MultiCell Immunotherapeutics Inc. subsidiary partnered to develop antibody-drug conjugates (ADCs) using Oxis’ OXS-2175 for triple-negative breast cancer (TNBC) and OXS-4235 for multiple myeloma (MM). MultiCell will develop three ADCs containing the two...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Oxis management update

Oxis International Inc. (OTCBB:OXIS; Euronext:OXI), Beverly Hills, Calif.   Business: Nutraceuticals, Autoimmune, Inflammation   Resigned: Ken Eaton as CEO and a director   Transitioned: Anthony Cataldo to CEO, while remaining chairman of Oxis and president...